Clinical effect of Shexiang Baoxin pill combined with sacubitril/valsartan in the treatment of acute myocardial in-farction after percutaneous coronary intervention
Objective To investigate the clinical effect of Shexiang Baoxin pill combined with sacubitril/valasrtan in the treatment of acute myocardial infarction after percutaneous coronary intervention(PCI).Methods A total of 120 patients with acute myocardial infarction from January 2021 to November 2023 after PCI were selected and randomly assigned to observation group(60 cases)and control group(60 cases)in Chuzhou First People's Hospital.The patients in both groups were given anticoagulation,antiplatelet,lipid-regulating,and other conventional treatment,while the control group was treated with sacubitril/valsartan,and the observation group was treated with sacubitril/valsartan combined with Shexiang Baoxin pill.The indexes including the changes of C-reactive protein(CRP),N-terminal pro-brain natriuretic peptide(NT-proBNP),blood pressure,left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),fractional shortening(FS)rate,left ventricular ejection fraction(LVEF)were compared between the two groups.The incidence of arrhythmia and length of stay during hospitalization and the rate of re-hospitalization within six months due to adverse cardiac events were also compared between the two groups.Results After 4-week treatment,the levels of CRP and NT-proBNP in the observation group were significantly lower than those in the control group(all P<0.05).After 6-month treatment,the cardiac color ultrasound ultrasonography indexes(LVEDD,LVESD,FS,LVEF)in the observation group were better than those in the control group(all P<0.05).The incidence of atrial and ventricular arrhythmias in the observation group was lower than that in the control group duration of hospital stay(P<0.05),and length of hospitalization in the observation group was shorter than that in the control group(P<0.05).At the 6-month follow-up,the rate of rehospitalization in the observation group was lower than that in the control group(5.1%vs 26.3%,P<0.05).Conclusions The combination of Shexiang Baoxin pill and sacubitri/valsartan can effectively inhibit inflammatory response,reverse ventricular remodeling,improve cardiac function,reduce complications and improve prognosis in patients with acute myocardial infarction after PCI.
Acute myocardial infarctionShexiang Baoxin pillSacubitril/valsartanCardiac function
国家科技期刊平台
NSTL
万方数据
